Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model
Autore:
Elsasser-Beile, U; Ruhnau, T; Freudenberg, N; Wetterauer, U; Mengs, U;
Indirizzi:
Univ Freiburg, Dept Urol, Expt Res Grp, D-79104 Freiburg, Germany Univ Freiburg Freiburg Germany D-79104 es Grp, D-79104 Freiburg, Germany Univ Freiburg, Inst Pathol, D-7800 Freiburg, Germany Univ Freiburg Freiburg Germany D-7800 t Pathol, D-7800 Freiburg, Germany Madaus AG, Cologne, Germany Madaus AG Cologne GermanyMadaus AG, Cologne, Germany
Titolo Testata:
CANCER
fascicolo: 5, volume: 91, anno: 2001,
pagine: 998 - 1004
SICI:
0008-543X(20010301)91:5<998:AEORML>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
BACILLUS-CALMETTE-GUERIN; METHYL-N-NITROSOUREA; GALACTOSIDE-SPECIFIC LECTIN; TUMOR-NECROSIS-FACTOR; MONONUCLEAR-CELLS; LEUKEMIA-CELLS; A-CHAIN; CANCER; IMMUNOTHERAPY; CARCINOMA;
Keywords:
recombinant mistletoe lectin; rat urinary bladder carcinoma; N-methyl-N-nitrosourea; urothelial carcinogenesis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Elsasser-Beile, U Univ Freiburg, Dept Urol, Expt Res Grp, Stefan Meier Str8, D-79104 Freiburg, Germany Univ Freiburg Stefan Meier Str 8 Freiburg Germany D-79104
Citazione:
U. Elsasser-Beile et al., "Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model", CANCER, 91(5), 2001, pp. 998-1004

Abstract

BACKGROUND. The objective of this study was to determine the effect of intravesically applied, recombinant, galactoside specific mistletoe lectin (rML) on chemically induced tumor development in the urinary bladder of rats. METHODS. For tumor induction, rats were treated with four biweekly 1.5 mg doses of N-methyl-N-nitrosourea (NMU) intravesically (Weeks 0, 2, 4, and 6). The control group (n = 39 + 17 rats) received no other treatment. The four therapy groups also received rML twice weekly according to one of the following instillation regimens: 1) 30 ng rML per instillation from Week 8 to Week 13 (Group a: n = 14 rats), 2) 150 ng rML per instillation from Week 8 to Week 13 (Group b: n = 23 + 15 rats), 3) 30 ng rML per instillation from Week 14 to Week 19 (Group c: n = 22 rats), and 4) 150 ng rML per instillation from Week 14 to Week 19 (Group d: n = 19 rats). After the rats were asphyxiated at Week 21, the urinary bladders were excised in tote and examined histopathologically. To study the immunomodulatory effects of intra vesically applied rML, 17 animals from the control group and 15 animals from Groupb were asphyxiated at Week 13, and urinary bladder tissue was analyzed by semiquantitative reverse transcriptase-polymerase chain reaction analysis for mRNA expression of interferon-gamma, interleukin-10, and Fas ligand. RESULTS, By Week 21, atypical hyperplasia and neoplastic transformation were found in 82% of the animals in the control group. In contrast, in all four cohorts that were treated with rML, significantly lower rates of atypical hyperplasia and neoplastic transformation were found (Group a, 50%; Groupb, 52%: Group c, 45%; and Group d, 42%). By Week 13, in the bladder tissueof 15 rML-treated animals from Group b, lower expression of interleukin-10mRNA was measured, whereas the expression levels of interferon-gamma mRNA and Fas ligand mRNA were comparable to those of 17 animals from the controlgroup. CONCLUSIONS. The current data provide evidence for an inhibitory effect ofrML on experimental urothelial carcinogenesis that does not seem to be dueto interferon-gamma and/or interleukin-10 dependent mechanisms. (C) 2001 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 13:14:07